pipeline
Mono- Specific Antibody

Mono- Specific Antibody

YBL-006

Target Antibody Structure Indications Developmental Stage
PD-1 Mono- Specific Solid tumors Phase 1 clinical trial

Summary

YBL-006 is a monoclonal antibody discovered from our proprietary library that targets programmed cell death protein 1 (PD-1) and is currently undergoing Phase 1 clinical trials as a PD-1 immune checkpoint inhibitor. The binding of PD-L1 and PD-L2 proteins on the surface of cancer cells to PD-1 proteins on the surface of T cells causes T cells to become unable to properly recognize the cancer cells and, therefore, not attack them. YBL-006 is being developed independently by Y-Biologics, binding to PD-1 and inhibiting an immune escape mechanism of cancer cells.

Mechanism
of Action

Immune checkpoint Inhibitor (PD-1)

image

Research Papers & Conferences

Preclinical characterization of YBL-006, a fully human anti-PD-1 antibody being ready
for clinical studies., CANCER RESEARCH, 2020

Interim analysis of first-in-human phase 1 study to assess safety and efficacy of YBL-006, an anti-PD-1 antibody
in advanced solid tumor with exploratory biomarker analysis of tumor mutational burden and artificial intelligence
(AI)-powered spatial analysis of tumor-infiltrating lymphocytes., Journal of clinical oncology, 2021

Interim results of phase 1 dose escalation study of YBL-006, a novel anti-PD-1 monoclonal antibody in advanced solid tumors

Project Conference Title Link
YBL-006 AACR 2020 Preclinical characterization of YBL-006, a fully human anti-PD-1 antibody
being ready for clinical studies
ASCO 2021 Interim analysis of first-in-human phase 1 study to assess safety and efficacy of
YBL-006, an anti-PD-1 antibody in advanced solid tumor with exploratory
biomarker analysis of tumor mutational burden and artificial intelligence
(AI)-powered spatial analysis of tumor-infiltrating lymphocytes
ESMO 2021 Interim results of phase 1 dose escalation study of YBL-006, a novel anti-PD-1 monoclonal antibody in advanced solid tumors

Preclinical & Clinical Data

  • Functional Assay

    image

    YBL-006 inhibits the interaction between PD-1 and PD-L1 to activate immune cells.

  • Open-label, multicenter, single-arm, Phase 1 clinical trial with dose escalation/expansion study on YBL-006 in patients with advanced solid cancer

    [Tumor Response to YBL-006]

    image

    In the dose escalation cohort, 1 CR, 1 PR, and 2 SD were observed following the administration of YBL-006.

  • [Changes in Target Lesion Size over Time]

    image

    Changes in the target lesion size were maintained during the follow-up observation period.

YBL-011

Target Antibody Structure Indications Development Stage
LAG-3 Mono- Sepecific Solid tumors CMC

Summary

LAG-3, a protein expressed on activated T cells or regulatory T cells (Tregs) (CD4+ or CD8+), inhibits T cell activation by binding MHC class II molecules or LSECtin on antigen presenting cells (APCs) or cancer cells, thereby enabling immune escape by cancer cells. YBL-011 targets LAG-3 on the surface of T cells, preventing binding to MHC class II molecules on APCs or cancer cells, simultaneously enhancing T cell activity and suppressing Treg cell activity to induce cancer cell death.

Mechanism
of Action

Immune checkpoint inhibitor

image

YBL-003

Target Antibody Structure Indications Development Stage
VSIG4 Mono- Sepecific Solid tumors Discovery

Summary

YBL-003 is an immune checkpoint inhibitor being developed as a therapeutic antibody candidate for the treatment of solid tumors. It regulates the function of macrophages and activity of T cells to reactivate the immune system in the tumor microenvironment and kill cancer cells. Furthermore, the scope of the indications for YBL-003 can be expanded to include gastric cancer, lung cancer, breast cancer, and more, illustrating its high potential for use as an immuno-oncology agent targeting solid tumors.

Mechanism
of Action

Immune checkpoint inhibitor

AR087

Target Antibody Structure Indications Development Stage
Undisclosed Mono- Specific Solid tumors Lead candidate

Summary

AR087 is an immuno-oncology agent that activates immune cells and kills cancer cells by binding to a target antigen expressed on cancer cells. Y-Biologics plans to develop AR087 as a therapeutic agent for various solid tumors through a joint research collaboration with HK inno.N.